Experiencia de uso de partículas DC Bead® cargadas con doxorrubicina en quimioembolización hepática

Muros-Ortega, M.; Díaz-Carrasco, María Sacramento; Vila-Clérigues, N.; Mendoza-Otero, F.; Rubia, A. de la; Alemán, Antonio Capel

doi:10.1016/j.farma.2010.06.006

Farmacia Hospitalaria

2011

DOI: 10.1016/j.farma.2010.06.006

|View full text |Cite

Experiencia de uso de partículas DC Bead® cargadas con doxorrubicina en quimioembolización hepática

M. Muros-Ortega

María Sacramento Díaz-Carrasco

N. Vila-Clérigues

et al.

Abstract: Using doxorubicin-loaded microspherical DC Beads(®) during transarterial chemoembolisation has been adapted to uses with scientific evidence and tolerated by all patients. Incidences during administration were mild and were resolved with symptomatic medication.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2015

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

New progress of non-surgical treatments for hepatocellular carcinoma

Cheng

2013

Med Oncol

View full text Add to dashboard Cite

Many non-surgical treatments of hepatocellular carcinoma (HCC) have significantly improved in the last few decades and have shown survival benefits for selected patients with HCC. Today ablation can improve survival in individuals diagnosed in early HCC and even offer a curative treatment in selected candidates. Patients with intermediate-stage HCC benefit from transarterial chemoembolization (TACE). Drug-eluting bead transarterial chemoembolization (DEB-TACE) has shown a better combined ischemic and cytotoxic effect locally and less system toxicity when compared with conventional TACE. Those diagnosed at advanced stage benefit from sorafenib. In addition to TACE and sorafenib which could improve survival for selected patients, three-dimensional conformal radiotherapy treatment (3-DCRT), selection internal radiation therapy and systemic chemotherapy have also shown anti-tumor activity in the treatment of advanced HCC, but their survival benefit have not been proven. The limited effects of single therapy suggested that the combination would enhance the overall treatment effect. Other potential non-surgical therapies like gene therapy and immunotherapy are still in testing phases, except for some small-scale clinical trials which have been reported to show some beneficial effect. Here, we review the current non-surgical treatments in HCC and the new advances in this field.

show abstract

New progress of non-surgical treatments for hepatocellular carcinoma

Cheng

2013

Med Oncol

View full text Add to dashboard Cite

show abstract

Quimioembolización transarterial con partículas liberadoras de doxorrubicina frente a quimioembolización transarterial convencional en carcinomas hepatocelulares irresecables: un estudio de eficacia, seguridad y gastos

et al. 2015

View full text Add to dashboard Cite

Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs

Vericat

Marcos

Briz

et al. 2015

Radiología (English Edition)

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Experiencia de uso de partículas DC Bead® cargadas con doxorrubicina en quimioembolización hepática

Abstract: Using doxorubicin-loaded microspherical DC Beads(®) during transarterial chemoembolisation has been adapted to uses with scientific evidence and tolerated by all patients. Incidences during administration were mild and were resolved with symptomatic medication.

Cited by 3 publications

References 20 publications

New progress of non-surgical treatments for hepatocellular carcinoma

New progress of non-surgical treatments for hepatocellular carcinoma

Quimioembolización transarterial con partículas liberadoras de doxorrubicina frente a quimioembolización transarterial convencional en carcinomas hepatocelulares irresecables: un estudio de eficacia, seguridad y gastos

Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs

Contact Info

Product

Resources

About